Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast c... by Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin

Get full text

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS) by Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, Sangeetha M. Reddy, Leisha A. Emens, Thomas M. Kuntz, Carolina Alves Costa Silva, Saud H. AlDubayan, Hoyin Chu, Beth Overmoyer, Paulina Lange, Molly K. DiLullo, Meagan Montesion, Julie Kasparian, Melissa E. Hughes, Victoria Attaya, Ameer Basta, Nancy U. Lin, Nabihah Tayob, Rinath Jeselsohn, Elizabeth A. Mittendorf, Sara M. Tolaney

Get full text